Brain SPECT analysis by 3D-SSP and phenotype of Parkinson's disease

Mito, Yasunori; Yoshida, Kazuto; Yabe, Ichiro; Makino, Kenichi; Tashiro, Kunio; Kikuchi, Seiji; Sasaki, Hidenao

doi:10.1016/j.jns.2005.10.017

Cited by 31 publications

(23 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Atrophy in the limbic and paralimbic regions occurs in patients with PD without dementia, though less markedly so than in patients with PDD. 29,30 Metabolic abnormalities in the posterior cingulate regions 31,32 and cerebral blood flow reduction in the anterior cingulate cortex 33,34 have been reported in patients with PDD. A reduction in cerebral blood flow in the posterior cingulate cortex has also been reported in PDD.…”

Section: Discussionmentioning

confidence: 99%

White Matter Alteration of the Cingulum in Parkinson Disease with and without Dementia: Evaluation by Diffusion Tensor Tract–Specific Analysis

Kamagata¹,

Motoi²,

Abe³

et al. 2012

AJNR Am J Neuroradiol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

White Matter Alteration of the Cingulum in Parkinson Disease with and without Dementia: Evaluation by Diffusion Tensor Tract–Specific Analysis

Kamagata¹,

Motoi²,

Abe³

et al. 2012

AJNR Am J Neuroradiol

View full text Add to dashboard Cite

show abstract

“…N-isopropyl-4-[ 123 I]iodoamphetamine ( 123 I-IMP) has been utilized for cerebral perfusion imaging with single photon emission computed tomography (SPECT) [1][2][3][4][5][6]. Using 123 I-IMP and SPECT, several methods have been developed for the quantitative measurement of cerebral blood fl ow (CBF).…”

Section: Introductionmentioning

confidence: 99%

N-isopropyl-4-[123I]iodoamphetamine (123I-IMP) products: a difference in radiochemical purity, unmetabolized fraction, and octanol extraction fraction in arterial blood and regional brain uptake in rats

et al. 2007

View full text Add to dashboard Cite

N-isopropyl-4-[123I]iodoamphetamine (123I-IMP) is a lipophilic compound utilized for cerebral blood flow (CBF) measurement with single photon emission computed tomography (SPECT). Two different 123I-IMP products (IMP(A) and IMP(B)) are commercially available. We examined the radiochemical purity, unmetabolized fraction, and octanol extraction fraction in arterial blood, and the regional brain uptake of IMP(A) and IMP(B) in a rat model. IMP(B) (96.4% +/- 0.08%, P < 0.05) showed significantly higher radiochemical purity than IMP(A) (95.5% +/- 0.20%). The mean unmetabolized fraction in arterial blood taken at 10 min after intravenous administration of IMP(B) (69.5% +/- 4.4%, P < 0.01) was significantly higher than that of IMP(A) (59.6% +/- 2.6%). The mean octanol extraction fraction of IMP(B) (75.0% +/- 1.3%, P < 0.01) was also significantly higher than that of IMP(A) (67.2% +/- 0.8%). The mean levels of radioactivity in arterial blood sampled at 10 min after injection and mean regional brain radioactivity (cerebral cortices, basal ganglia, brain stem, and cerebellum) at 10-12 min after injection were not significantly different between IMP(A) and IMP(B). The present study indicates differences in the radiochemical purity and the unmetabolized and octanol extraction fraction in arterial blood between the two commercially available 123I-IMP products. The appropriate octanol extraction fractions for IMP(A) and IMP(B) should be determined in humans and employed for quantitative CBF measurement in clinical SPECT.

show abstract

“…Second, the relationship between GM atrophy and clinical symptoms was evaluated in specific regions of interest (ROIs) that were found to be related to PD. 12,[14][15][16] Finally, in regions that showed such a relationship, the association between GM atrophy and functional connectivity within the motor network was examined.…”

mentioning

confidence: 99%

Gray matter atrophy distinguishes between Parkinson disease motor subtypes

Rosenberg‐Katz

Herman²,

Jacob³

et al. 2013

Neurology

150

110

View full text Add to dashboard Cite

Objective: To assess differences in gray matter (GM) atrophy between 2 Parkinson disease (PD) subtypes: the tremor dominant (TD) subtype and the postural instability gait difficulty (PIGD) subtype.Methods: Patients were classified as belonging to the predominately PIGD (n 5 30) or predominately TD (n 5 29) subtype. Voxel-based morphometry was used to compare GM in these 2 subtypes and to evaluate correlations between predefined regions of interest and the degree of symptoms. In the regions where GM atrophy was associated with symptoms, the relationship between GM volumes and functional connectivity was examined.Results: GM was reduced in the predominately PIGD group, compared with the predominately TD group, in areas that involve motor, cognitive, limbic, and associative functions (p , 0.05, false discovery rate corrected). Lower GM volumes in the pre-supplementary motor area (SMA) and in the primary motor area were associated with increased severity of PIGD symptoms (r 5 20.42, p , 0.001; r 5 20.38, p , 0.003, respectively). Higher GM volumes within the pre-SMA were associated with stronger functional connectivity between the pre-SMA and the putamen (r 5 0.415, p , 0.025) in the patients with predominately PIGD. Conclusions:In patients with PD, PIGD symptoms are apparently associated with GM atrophy in motor-related regions and decreased functional connectivity. GM degeneration and a related decrease in spontaneous coactivation between cortical and subcortical motor-planning areas may partially account for the unique clinical characteristics of a subset of patients with PD.

show abstract

Brain SPECT analysis by 3D-SSP and phenotype of Parkinson's disease

Cited by 31 publications

References 33 publications

White Matter Alteration of the Cingulum in Parkinson Disease with and without Dementia: Evaluation by Diffusion Tensor Tract–Specific Analysis

White Matter Alteration of the Cingulum in Parkinson Disease with and without Dementia: Evaluation by Diffusion Tensor Tract–Specific Analysis

N-isopropyl-4-[123I]iodoamphetamine (123I-IMP) products: a difference in radiochemical purity, unmetabolized fraction, and octanol extraction fraction in arterial blood and regional brain uptake in rats

Gray matter atrophy distinguishes between Parkinson disease motor subtypes

Contact Info

Product

Resources

About